Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. Issue 8 (10th March 2022)

• Record Type: Journal Article
• Authors: Fahrmann, Johannes F.; Marsh, Tracey; Irajizad, Ehsan; Patel, Nikul; Murage, Eunice; Vykoukal, Jody; Dennison, Jennifer B.; Do, Kim-Anh; Ostrin, Edwin; Spitz, Margaret R.; Lam, Stephen; Shete, Sanjay; Meza, Rafael; Tammemägi, Martin C.; Feng, Ziding; Hanash, Samir M.
• Is Part Of: Journal of clinical oncology. Volume 40:Issue 8(2022)
• Page Start: 876
• Page End: 883
• Publication Date: 2022-03-10
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.21.01460
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : PURPOSE: To investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics. METHODS: A blinded validation study was performed using prostate lung colorectal ovarian (PLCO) Cancer Screening Trial data and biospecimens to evaluate the performance of a four-marker protein panel (4MP) consisting of the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment in combination with a lung cancer risk prediction model (PLCOm2012 ) compared with current US Preventive Services Task Force (USPSTF) screening criteria. The 4MP was assayed in 1, 299 sera collected preceding lung cancer diagnosis and 8, 709 noncase sera. RESULTS: The 4MP alone yielded an area under the receiver operating characteristic curve of 0.79 (95% CI, 0.77 to 0.82) for case sera collected within 1-year preceding diagnosis and 0.74 (95% CI, 0.72 to 0.76) among the entire specimen set. The combined 4MP + PLCOm2012 model yielded an area under the receiver operating characteristic curve of 0.85 (95% CI, 0.82 to 0.88) for case sera collected within 1 year preceding diagnosis. The benefit of the 4MP in the combined model resulted from improvement in sensitivity at high specificity. Compared with the USPSTF2021 criteria, the combined 4MP + PLCOm2012 model exhibited statistically significant improvements in sensitivity and specificity. Among PLCO participants with ≥ 10 smoking pack-years, the 4MP + PLCOm2012 model would have identified for annual screening 9.2% more lung cancer cases and would have reduced referral by 13.7% among noncases compared with USPSTF2021 criteria. CONCLUSION: A blood-based biomarker panel in combination with PLCOm2012 significantly improves lung cancer risk assessment for lung cancer screening.